Adjunct to Gleevec enhances therapeutic effects

[Guest guest]

Individuals with chronic myeloid leukemia (CML) are first treated with a drug

known as imatinib mesylate. Although very effective, as the disease progresses

it often becomes resistant to the drug. However, a team of researchers, at the

University of Leicester, United Kingdom, and Jefferson University,

Philadelphia, has identified a class of drugs that might enhance the therapeutic

effects of imatinib mesylate and other drugs that target the same molecule. The

team, led by Paolo Salomoni and Bruno Calabretta, observed that for several

different CML cell lines and primary cells, although imatinib mesylate killed

the majority of cells, a marked proportion underwent a process known as

autophagy. Consistent with studies indicating that the induction of autophagy

can provide a mechanism of cellular survival, suppression of autophagy using

either drugs or RNA interference enhanced imatinib mesylate–induced death of CML

cell lines, primary CML cells, and CML stem cells. The authors therefore suggest

that inhibitors of autophagy might be used with imatinib mesylate or other drugs

that target the same molecule to enhance their therapeutic benefits.

Entired article copied from this web site:

http://esciencenews.com/articles/2009/04/13/enhancing.effects.drug.used.treat.ch\

ronic.myeloid.leukemia

Source: Journal of Clinical Investigation

*************************

Autophagy (read here)-

http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/A/Autophagy.html

FYI,

Lottie

R

[Guest guest]

Dear Lottie,

Do you have a hillbilly translation of your e-mail? The one you sent doesn't

seem to be in Indiana English!

Bob , Granger, Indiana

>

> Individuals with chronic myeloid leukemia (CML) are first treated with a drug

known as imatinib mesylate. Although very effective, as the disease progresses

it often becomes resistant to the drug. However, a team of researchers, at the

University of Leicester, United Kingdom, and Jefferson University,

Philadelphia, has identified a class of drugs that might enhance the therapeutic

effects of imatinib mesylate and other drugs that target the same molecule. The

team, led by Paolo Salomoni and Bruno Calabretta, observed that for several

different CML cell lines and primary cells, although imatinib mesylate killed

the majority of cells, a marked proportion underwent a process known as

autophagy. Consistent with studies indicating that the induction of autophagy

can provide a mechanism of cellular survival, suppression of autophagy using

either drugs or RNA interference enhanced imatinib mesylate–induced death of CML

cell lines, primary CML cells, and CML stem cells. The authors therefore suggest

that inhibitors of autophagy might be used with imatinib mesylate or other drugs

that target the same molecule to enhance their therapeutic benefits.

>

> Entired article copied from this web site:

>

>

http://esciencenews.com/articles/2009/04/13/enhancing.effects.drug.used.treat.ch\

ronic.myeloid.leukemia

>

> Source: Journal of Clinical Investigation

> *************************

> Autophagy (read here)-

http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/A/Autophagy.html

> FYI,

> Lottie

> R

>

>